Loading…
Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis
The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC...
Saved in:
Published in: | Journal of personalized medicine 2021-03, Vol.11 (3), p.187 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93 |
---|---|
cites | cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93 |
container_end_page | |
container_issue | 3 |
container_start_page | 187 |
container_title | Journal of personalized medicine |
container_volume | 11 |
creator | Orlandi, Armando Pontolillo, Letizia Mele, Caterina Pasqualoni, Mariangela Pannunzio, Sergio Cannizzaro, Maria Chiara Cutigni, Claudia Palazzo, Antonella Garufi, Giovanna Vellone, Maria Ardito, Francesco Franceschini, Gianluca Sanchez, Alejandro Martin Cassano, Alessandra Giuliante, Felice Bria, Emilio Tortora, Giampaolo |
description | The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months
16 months; HR 0.083,
< 0.0001) and DFI (16 months
5 months; HR 0.17,
= 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option. |
doi_str_mv | 10.3390/jpm11030187 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7998479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2504590294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</originalsourceid><addsrcrecordid>eNpdkc1rGzEQxUVoqIOTU-9B0EuhOBl97GrVQ8E1bRNwSGmSs9DKWkdmd-VIWoP_-ypxYtwIgYbRj8ebeQh9InDBmITL1bojBBiQShyhEwqimHBOyw8H9QidxbiCfKqC0hI-ohFjFQAp4QQt525jA76xScd8rUm-2-LG71vJGfwj2Fzime5NZv_knu1T_Ian-M71y9bi6z4ml4bkfI__2hR8XGelrIynvW630cVTdNzoNtqz13eMHn79vJ9dTea3v69n0_nEcJBpInVdGFvWcmFK4A2IRoIGycFQXbHSksZWgpOmZMBqKPOItQDKgS40NAsj2Rh93-muh7qzC5ONBt2qdXCdDlvltVP___TuUS39RgkpKy6eBb68CgT_NNiYVOeisW2re-uHqGiR1yiIICyjn9-hKz-EPPALxQsJVPJMfd1RJq8lBtvszRBQzxmqgwwzfX7of8--Jcb-Aap5mEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504590294</pqid></control><display><type>article</type><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</creator><creatorcontrib>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</creatorcontrib><description>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months
16 months; HR 0.083,
< 0.0001) and DFI (16 months
5 months; HR 0.17,
= 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11030187</identifier><identifier>PMID: 33800160</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Abscesses ; Age ; Breast cancer ; Cancer therapies ; Liver ; Metastases ; Metastasis ; Mortality ; Patients ; Precision medicine ; Software ; Surgery</subject><ispartof>Journal of personalized medicine, 2021-03, Vol.11 (3), p.187</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</citedby><cites>FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</cites><orcidid>0000-0002-2950-3395 ; 0000-0001-5253-4678 ; 0000-0002-2003-9434 ; 0000-0003-1596-2862</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2504590294/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2504590294?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33800160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orlandi, Armando</creatorcontrib><creatorcontrib>Pontolillo, Letizia</creatorcontrib><creatorcontrib>Mele, Caterina</creatorcontrib><creatorcontrib>Pasqualoni, Mariangela</creatorcontrib><creatorcontrib>Pannunzio, Sergio</creatorcontrib><creatorcontrib>Cannizzaro, Maria Chiara</creatorcontrib><creatorcontrib>Cutigni, Claudia</creatorcontrib><creatorcontrib>Palazzo, Antonella</creatorcontrib><creatorcontrib>Garufi, Giovanna</creatorcontrib><creatorcontrib>Vellone, Maria</creatorcontrib><creatorcontrib>Ardito, Francesco</creatorcontrib><creatorcontrib>Franceschini, Gianluca</creatorcontrib><creatorcontrib>Sanchez, Alejandro Martin</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Giuliante, Felice</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months
16 months; HR 0.083,
< 0.0001) and DFI (16 months
5 months; HR 0.17,
= 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</description><subject>Abscesses</subject><subject>Age</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Liver</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Software</subject><subject>Surgery</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc1rGzEQxUVoqIOTU-9B0EuhOBl97GrVQ8E1bRNwSGmSs9DKWkdmd-VIWoP_-ypxYtwIgYbRj8ebeQh9InDBmITL1bojBBiQShyhEwqimHBOyw8H9QidxbiCfKqC0hI-ohFjFQAp4QQt525jA76xScd8rUm-2-LG71vJGfwj2Fzime5NZv_knu1T_Ian-M71y9bi6z4ml4bkfI__2hR8XGelrIynvW630cVTdNzoNtqz13eMHn79vJ9dTea3v69n0_nEcJBpInVdGFvWcmFK4A2IRoIGycFQXbHSksZWgpOmZMBqKPOItQDKgS40NAsj2Rh93-muh7qzC5ONBt2qdXCdDlvltVP___TuUS39RgkpKy6eBb68CgT_NNiYVOeisW2re-uHqGiR1yiIICyjn9-hKz-EPPALxQsJVPJMfd1RJq8lBtvszRBQzxmqgwwzfX7of8--Jcb-Aap5mEw</recordid><startdate>20210308</startdate><enddate>20210308</enddate><creator>Orlandi, Armando</creator><creator>Pontolillo, Letizia</creator><creator>Mele, Caterina</creator><creator>Pasqualoni, Mariangela</creator><creator>Pannunzio, Sergio</creator><creator>Cannizzaro, Maria Chiara</creator><creator>Cutigni, Claudia</creator><creator>Palazzo, Antonella</creator><creator>Garufi, Giovanna</creator><creator>Vellone, Maria</creator><creator>Ardito, Francesco</creator><creator>Franceschini, Gianluca</creator><creator>Sanchez, Alejandro Martin</creator><creator>Cassano, Alessandra</creator><creator>Giuliante, Felice</creator><creator>Bria, Emilio</creator><creator>Tortora, Giampaolo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2950-3395</orcidid><orcidid>https://orcid.org/0000-0001-5253-4678</orcidid><orcidid>https://orcid.org/0000-0002-2003-9434</orcidid><orcidid>https://orcid.org/0000-0003-1596-2862</orcidid></search><sort><creationdate>20210308</creationdate><title>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</title><author>Orlandi, Armando ; Pontolillo, Letizia ; Mele, Caterina ; Pasqualoni, Mariangela ; Pannunzio, Sergio ; Cannizzaro, Maria Chiara ; Cutigni, Claudia ; Palazzo, Antonella ; Garufi, Giovanna ; Vellone, Maria ; Ardito, Francesco ; Franceschini, Gianluca ; Sanchez, Alejandro Martin ; Cassano, Alessandra ; Giuliante, Felice ; Bria, Emilio ; Tortora, Giampaolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abscesses</topic><topic>Age</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Liver</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Software</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orlandi, Armando</creatorcontrib><creatorcontrib>Pontolillo, Letizia</creatorcontrib><creatorcontrib>Mele, Caterina</creatorcontrib><creatorcontrib>Pasqualoni, Mariangela</creatorcontrib><creatorcontrib>Pannunzio, Sergio</creatorcontrib><creatorcontrib>Cannizzaro, Maria Chiara</creatorcontrib><creatorcontrib>Cutigni, Claudia</creatorcontrib><creatorcontrib>Palazzo, Antonella</creatorcontrib><creatorcontrib>Garufi, Giovanna</creatorcontrib><creatorcontrib>Vellone, Maria</creatorcontrib><creatorcontrib>Ardito, Francesco</creatorcontrib><creatorcontrib>Franceschini, Gianluca</creatorcontrib><creatorcontrib>Sanchez, Alejandro Martin</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Giuliante, Felice</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>Tortora, Giampaolo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orlandi, Armando</au><au>Pontolillo, Letizia</au><au>Mele, Caterina</au><au>Pasqualoni, Mariangela</au><au>Pannunzio, Sergio</au><au>Cannizzaro, Maria Chiara</au><au>Cutigni, Claudia</au><au>Palazzo, Antonella</au><au>Garufi, Giovanna</au><au>Vellone, Maria</au><au>Ardito, Francesco</au><au>Franceschini, Gianluca</au><au>Sanchez, Alejandro Martin</au><au>Cassano, Alessandra</au><au>Giuliante, Felice</au><au>Bria, Emilio</au><au>Tortora, Giampaolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2021-03-08</date><risdate>2021</risdate><volume>11</volume><issue>3</issue><spage>187</spage><pages>187-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>The liver represents the first metastatic site in 5-12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45-103) and 15 months (95% CI 11-46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months
16 months; HR 0.083,
< 0.0001) and DFI (16 months
5 months; HR 0.17,
= 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33800160</pmid><doi>10.3390/jpm11030187</doi><orcidid>https://orcid.org/0000-0002-2950-3395</orcidid><orcidid>https://orcid.org/0000-0001-5253-4678</orcidid><orcidid>https://orcid.org/0000-0002-2003-9434</orcidid><orcidid>https://orcid.org/0000-0003-1596-2862</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2075-4426 |
ispartof | Journal of personalized medicine, 2021-03, Vol.11 (3), p.187 |
issn | 2075-4426 2075-4426 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7998479 |
source | Open Access: PubMed Central; Publicly Available Content Database |
subjects | Abscesses Age Breast cancer Cancer therapies Liver Metastases Metastasis Mortality Patients Precision medicine Software Surgery |
title | Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20Metastasectomy%20for%20Metastatic%20Breast%20Cancer%20Patients:%20A%20Single%20Institution%20Retrospective%20Analysis&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Orlandi,%20Armando&rft.date=2021-03-08&rft.volume=11&rft.issue=3&rft.spage=187&rft.pages=187-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11030187&rft_dat=%3Cproquest_pubme%3E2504590294%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-9ab5ce6b9dc604f07f90a0940c2a836e1fe8741f6303b06075b702402da0fdc93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2504590294&rft_id=info:pmid/33800160&rfr_iscdi=true |